RESEARCH ABSTRACTS AND PRESENTATIONS

2026

• Abeyakoon C, et al. Proposed definition for ‘primary refractory’ disease in nodal peripheral T-cell lymphoma: an Australian-Canadian collaborative study. Poster presentation at: EHA2026 Congress; June 11-14, 2026; Stockholm, Sweden.
• Ganeshalingam V, et al. Immunohistochemical practice in the diagnosis of diffuse large B-cell lymphoma in Australia. Abstract at: EHA2026 Congress; June 11-14, 2026; Stockholm, Sweden.

2025

• Abeyakoon C, et al. Survival Outcomes in Nodal Peripheral T-cell Lymphoma following Primary and Second-line Treatment: An Australasian-Canadian Collaborative Study. Abstract at: 18th International Conference on Malignant Lymphoma; June 17-22, 2025; Lugano, Switzerland.
• Abeyakoon C, et al. End-of-treatment PET/CT Complete Remission is Highly Prognostic in Nodal Peripheral T-cell Lymphoma: An Australasian-Canadian Collaborative Study. Poster presentation at: 18th International Conference on Malignant Lymphoma; June 17-22, 2025; Lugano, Switzerland.
• Chung E, et al. Determining the prognostic significance of the Ki67 proliferation index in treatment-naïve follicular lymphoma: An Australasian Lymphoma Registry (LaRDR) study. Poster presentation at: 18th International Conference on Malignant Lymphoma; June 17-22, 2025; Lugano, Switzerland.
• Chung E, et al. Determining the Prognostic significance of the Ki67 proliferation index in treatment-naïve follicular lymphoma: An Australasian Lymphoma and Related Diseases Registry (LaRDR) study. Abstract Book at: EHA2025 Congress; June 12-15, 2025; Milan, Italy.
• Chung E, et al. Determining the prognostic significance of the Ki67 proliferation index in treatment-naïve follicular lymphoma: An Australasian Lymphoma Registry (LaRDR) study. Oral presentation at: BLOOD 2025; October 26-29, 2025; Perth, Australia.

2024

• Sungur S, et al. Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study. Poster presentation at: 66th ASH Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.
• Yao Y, et al. Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study. Poster presentation at: 66th ASH Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.
• Chung E, et al. Comparing outcomes using registry versus clinician definitions of bulky disease in lymphoma care: An Australasian Lymphoma Registry (LaRDR) study. Oral presentation at: ACTA 2024 Clinical Trials and Registries Symposium; December 2-4, 2024; Melbourne, Australia
• Chung E, et al. Definition and Use of Bulky Disease in Lymphoma Care: A Study from the Australasian Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2024; October 27-30, 2024; Brisbane, Australia.
• Smyth E, et al. High-risk diffuse large B-cell lymphoma in young patients: A retrospective registry study of management practices and outcomes in Australia. Poster presentation at: BLOOD 2024; October 27-30, 2024; Brisbane, Australia.
• Viiala NO, et al. Platinum substitution in salvage chemotherapy for relapsed/refractory non-Hodgkin lymphoma: a LaRDR Study. Poster presentation at: BLOOD 2024; October 27-30, 2024; Brisbane, Australia.
• Wang L, et al. The Definition and Use of Bulk Disease in Phase 3 Lymphoma Trials: A Comprehensive Literature Review. Poster presentation at: BLOOD 2024; October 27-30, 2024; Brisbane, Australia.
• Chung E, et al. Definition and Use of Bulky Disease in Lymphoma Care: A Study from the Australasian Lymphoma and Related Diseases Registry (LaRDR), Abstract Book at: EHA2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.
• Wang L, et al. The Definition and Use of Bulk Disease in Phase 3 Lymphoma Trials: A Comprehensive Literature Review. Abstract Book at: EHA2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.

2023

• Al-Mashhadi AL, et al. Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up. Poster presentation at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, California.
• Shaw B, et al. Efficacy of polatuzumab combinations in relapsed/refractory diffuse large B cell lymphoma (RRDLBCL) trial-ineligible patients: a study from the Australian and New Zealand Lymphoma and Related Diseases Registry. Abstract Book at: BLOOD 2023; November 5-8, 2023; Melbourne, Australia.
• Wong E, et al. Real-world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR). Oral presentation at: Canberra Health Annual Research Meeting 2023; July 18 -21, 2023; Canberra, Australia.
• Shaw B, et al. Polatuzumab, bendamustine & rituximab (Pola-BR) efficacy in relapsed/refractory trial-ineligible large B cell lymphoma patients: An Australian Lymphoma Registry (LaRDR) study. Abstract Book at: 17th International Conference on Malignant Lymphoma; June 13-17, 2023; Lugano, Switzerland.
• Shaw B, et al. Polatuzumab, bendamustine & rituximab (Pola-BR) efficacy in relapsed/refractory diffuse large B cell lymphoma (RRDLBCL) trial-ineligible patients: an Australian Lymphoma Registry (LaRDR) study. Abstract Book at: EHA2023 Hybrid Congress; June 8-15, 2023; Frankfurt, Germany.

2022

• Goh Z, et al. Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study. Poster presentation at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, Los Angeles.
• Rodday AM, et al. Development and Validation of the Advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Oral presentation at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, Los Angeles.
• Bhopal S, et al. Defining the demographics, clinical presentation, and management of Australian patients with chronic lymphocytic leukaemia (CLL) on the Lymphoma and Related Diseases Registry (LaRDR), 2016 to 2021. Poster presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.
• Chai K, et al. Infection patterns and outcomes in patients with newly diagnosed CLL and NHL – Preliminary results from the Immunoglobulin use and Outcomes in CLL and NHL (ICAN) study. Oral presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.
• Goh Z, et al. Characteristics and Outcomes of Elderly Patients with classicial Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Diseases Registry (LaRDR) Study. Poster presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.
• Ratnasingam S, et al. Patient characteristics and management of aggressive lymphoma in metropolitan and non-metropolitan centres in Australia from the Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.
• Wong E, et al.. Real-world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR). Oral presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.

2021

• Walker SK, et al. Real World Data on the Outcomes of Richter’s Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study. Poster presentation at: 63rd ASH Annual Meeting and Exposition; December 10-14, 2021; Atlanta, Georgia.
• Baggio D, et al. Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian cohort: an analysis of the Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Baggio D, et al. Ibrutinib in relapsed/refractory chronic lymphocytic leukaemia: interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry. Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Baggio D, et al. Ibrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL): interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry. Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Nguyen J, et al. Clinical characteristics of Australian treatment-naïve classical Hodgkin Lymphoma (cHL) patients from the Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Opat S, et al. Real world management of Lymphoma and Related diseases in Australia: The first five years of the Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Shipton M, et al. Patterns of treatment and outcomes in patients with large B-cell lymphoma: The Australian real-world experience. Oral presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Baggio D. Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian context: an analysis of the Lymphoma and Related Diseases Registry. Oral presentation at: 13th Annual T-cell Lymphoma Forum; July 8-10, 2021.

2020

• Hawkes E. Achieving International Guidelines on PTCL: Are we closer to Global Standards of Care? The Australian TCL landscape. Oral presentation at: 12th Annual T-Cell Lymphoma Forum; February 3, 2020; San Diego, California. 

2019

• Barraclough A, et al. The ‘Real World’ Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. Poster presentation at: 61st ASH Annual Meeting and Exposition; December 7-10, 2019; Orlando, Florida.
• Barraclough A, et al. Utility of GELF criteria in treatment decisions for follicular lymphoma (FL) treated in clinical practice. Poster presentation at: BLOOD 2019; October 20-23, 2019; Perth, Australia.
• Clugston S, et al. Decision-making in CNS prophylaxis for DLBCL in a single institution. Poster presentation at: BLOOD 2019; October 20-23, 2019; Perth, Australia.
• St George G, et al. The Lymphoma and Related Diseases Registry (LaRDR): A post-pilot update. Poster presentation at: BLOOD 2019; October 20-23, 2019; Perth, Australia.
• Yoo E, et al, Treatment patterns and outcomes of patients with follicular lymphoma (FL) at Sir Charles Gairdner Hospital (SCGH): An analysis of data from the Lymphoma and related diseases registry (LaRDR). Poster presentation at: BLOOD 2019; 2019 October 20-23; Perth, Australia.
• Tohidi-Esfahani I, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study In CArt-wheeL): A Global Patient-derived Data Registry mapping treatment and quality of life data. Poster presentation at: ICML 2019; June 18-22, 2019; Lugano, Switzerland.
• Tohidi-Esfahani I, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study In CArt-wheeL): A Global Patient-derived Data Registry mapping treatment and quality of life data. Poster presentation at: 24th Congress of EHA; June 13-16, 2019; Amsterdam, The Netherlands.

2018

• Dickinson M, et al. High rates of early treatment failure in diffuse large B-cell lymphoma: early results from the Lymphoma and Related Diseases Registry. Poster presentation at: BLOOD 2018; October 21-24, 2018; Brisbane, Australia.
• Xu K, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study Involving CArt-wheeL): Creating robust patient-reported data for observational research. Poster presentation at: BLOOD 2018; October 21-24, 2018; Brisbane, Australia.
• Tohidi-Esfahani I, et al. WhiMSICAL (Waldenström’s aldenström’s Macroglobulinemia Study Involving CArt-wheeL): A Global WM Registry for the Patient’s Voice. Poster presentation at: 10th International Workshop on Waldenström’s Macroglobulinemia; October 11-13, 2018; Manhattan, New York.
• Talaulikar D, et al. A national pathology review committee for the Lymphoma and Related Diseases Registry. Poster presentation at: RCPA Pathology Update 2018; March 2-4, 2018; Sydney, Australia.

2017

• Rowsell L, et al. The Lymphoma and Related Diseases Registry (LaRDR): Improving the quality of care for lymphoma patients. Poster presentation at: HAA 2017; October 29-November 1, 2017; Sydney, Australia.
• Tohidi-Esfahani I, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study Involving CArt -wheeL) update: Empowering patients internationally to contribute data for research. Poster presentation at: HAA 2017; October 29 –November 1, 2017; Sydney, Australia.

2016

• Morrison J, et al. Real world management of lymphoma: Development of the Australian and New Zealand Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: HAA 2016; November 13-16, 2016; Melbourne, Australia.

ABSTRACTS AND PRESENTATIONS FROM CONSORTIA

2026

• Bushuieva M, et al. Outcomes and prognostic risk factors in nodal peripheral T-cell lymphoma. Results from the International T-Cell Project 2.0 Prospective Cohort Study. Poster presentation at: EHA2026 Congress; June 11-14, 2026; Stockholm, Sweden.
• Chung E, et al. Mapping the methodology & attributes of global lymphoma registries: A Lymphoma Registry Alliance (LyRA) Initiative. Poster presentation at: EHA2026 Congress; June 11-14, 2026; Stockholm, Sweden.
• Iyengar S, et al. ERIC real-world retrospective analysis of outcomes in CLL patients treated with chemotherapy-free frontline targeted therapies demonstrates the impact of TP53 disruption in the era of novel therapy. Poster presentation at: EHA2026 Congress; June 11-14, 2026; Stockholm, Sweden.
• Shokun N, et al. Real-world insights into clinical features and outcomes in extranodal T-cell lymphomas: results from the International T-Cell Project 2.0 Prospective Cohort Study. Poster presentation at: EHA2026 Congress; June 11-14, 2026; Stockholm, Sweden.
• Shokun N, et al. Autologous bone marrow transplantation. Insights from International T-Cell Project 2.0. Poster presentation at: EHA2026 Congress; June 11-14, 2026; Stockholm, Sweden.

2025

• Cui Z, Rodday AM, Tighiouart H, Counsell N, Rossetti S, Upshaw J, Kirkwood A, Li H, Advani R, Casasnovas O, Cerhan J, Federico M, Gallamini A, Ghesquieres H, Hawkes E, Hodgson D, Hutchings M, Johnson P, Link B, Mou E, Radford J, Savage K, Stephens D, Zinzani PL, Maurer M, Rossi C, Evens A, Parsons S. PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course. Oral presentation American Society of Hematology 67th annual meeting. Orlando, FL. December 2025.

2024

• Maurer M, Parsons SK, Upshaw J, Rodday AM, Friedberg, JW, Gallamini A, Federico M, Hawkes E, Hodgson D, Johnson P, Mou E, Savage K, Zinzani PL Evens A. Identification of Risk Categories and Stratification from the Advanced-Stage Hodgkin Lymphoma (AS-HL) International Prognostic Index (A-HIPI) Model. Presented at the International Symposium on Hodgkin Lymphoma (ISHL13). Cologne, Germany. October 2024. HemaSphere. 2024 Oct; 8 (S2): e70012
• Rodday AM*, Parsons SK* (*co-first authors), Cui ZJ, Xiang Q, Counsell N, Rossetti, Upshaw JN, Williams ALM, Kirkwood AA, Li H, Cerhan JR, Federico M, Friedberg JW, Gallamini A, Hawkes EA, Hodgson D, Johnson P, Link BK, Mou E, Radford J, Savage KJ, Stephens DM, Zinzani PL, Maurer MJ, Evens AM. Creation of a multistate model to improve prognostication across the disease course in advanced stage classic Hodgkin lymphoma (cHL): A Report from the HoLISTIC Consortium. Oral presentation at the 66th annual meeting of the American Society of Hematology. San Diego, CA. December 2024. Blood. 2024 Nov; 144 (Supplement 1): 567.

2023

• Evens AM, et al. Development and Validation of the Early-Stage Hodgkin Lymphoma International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Poster presentation at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, California.
• Maurer MJ, et al. Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Poster presentation at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, California.
• Manni M, et al. Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T-cell Project 2.0. Poster presentation at: 17th International Conference on Malignant Lymphoma; June 13-17, 2023; Lugano, Switzerland.
• Parsons SK, Heneghan MB, Rodday AM, Friedberg J, Gallamini A, Hawkes E, Hodgson D, Johnson P, Link B, Maurer M, Nelson J, Savage K, Upshaw J, Zinzani PL, Evens A. Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium. Presented at the 5th International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL). Memphis, TN. October 2023.

2021

• Federico M, et al. Subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International Prospective T-cell Project 2.0. E-poster gallery at: 16th International Conference on Malignant Lymphoma; June 18-22, 2021; Lugano, Switzerland.